What Is a CD4 Cell and Why Does It Matter in HIV?
CD4 T-cells (also called T-helper cells or CD4+ lymphocytes) are a type of white blood cell that plays a central role in coordinating the immune response. They recognise foreign pathogens, activate other immune cells (CD8 T-cells, B-cells, macrophages), and orchestrate the immune response that eliminates infections.
HIV specifically targets CD4 cells — the virus uses the CD4 receptor on the cell surface to gain entry, then replicates inside the cell and destroys it. Over years of untreated HIV infection, the CD4 count falls progressively as the virus destroys more cells than the immune system can replace. When CD4 falls below critical thresholds, the immune system can no longer defend against pathogens that a healthy immune system would easily eliminate — these are the opportunistic infections (OIs) that define AIDS.
Normal CD4 vs HIV-Infected
A healthy HIV-negative adult has a CD4 count of 500–1,500 cells/mm³. In HIV infection without treatment, CD4 declines at approximately 50–100 cells/mm³ per year — reaching the AIDS-defining threshold of 200 in roughly 3–10 years. Individual variation is high — some people are “rapid progressors” who fall quickly; others are “long-term non-progressors” whose CD4 remains stable for decades. ART halts this decline and produces recovery.
The CD4 Count Range — What Each Level Means
Each CD4 level corresponds to a different degree of immune compromise and different clinical risks. The zones below are clinical thresholds — not absolute cutoffs — that guide management decisions.
CD4 Count Range — cells/mm³
Green = adequate immune function → Red = severe immune compromise
Most severe OIs. CMV retinitis, disseminated MAC. Urgent ART + OI treatment.
PCP, toxoplasma, cryptococcal risk. Cotrimoxazole prophylaxis. CrAg screen.
TB risk elevated. Bacterial pneumonia. Continue cotrimoxazole. ART essential.
Good ART response. Most OI risks reducing. Continue ART + 6-monthly monitoring.
Near-normal immunity. Stop cotrimoxazole if CD4 >200 for 6+ months. Annual monitoring.
What Opportunistic Infections Occur at Each CD4 Level
Opportunistic infections are caused by organisms that a healthy immune system would eliminate without illness. In HIV, as CD4 falls below specific thresholds, these pathogens find an immune system that can no longer control them. Knowing the thresholds allows prevention — cotrimoxazole prophylaxis, CrAg screening, and ART together prevent the majority of OIs.
| CD4 Level | Opportunistic Infections | Prevention | Action |
|---|---|---|---|
| <50 | CMV retinitis (blindness), disseminated MAC, microsporidiosis, PML. Most severe OIs. | ART is the primary prevention. No specific prophylaxis for CMV/MAC until ART immune recovery. | Urgent ART. Ophthalmology referral for CMV retinitis if visual symptoms. |
| 50–100 | Cryptococcal meningitis, toxoplasma encephalitis, PCP, CMV. High mortality if missed. | CrAg screen (serum cryptococcal antigen). Pre-emptive fluconazole if CrAg positive. Cotrimoxazole for PCP + toxoplasma. | CrAg test at diagnosis. Cotrimoxazole started. ART urgently. |
| 100–200 | PCP (Pneumocystis pneumonia), toxoplasma, oesophageal candidiasis, TB. AIDS-defining threshold. | Cotrimoxazole prophylaxis started. TB screening mandatory. | Start cotrimoxazole. Screen and exclude TB. ART. |
| 200–350 | TB (20–30× higher risk), bacterial pneumonia, oral candidiasis, herpes zoster. | Cotrimoxazole continued. TB screening at every visit. Isoniazid preventive therapy (IPT) if IGRA positive. | Continue cotrimoxazole. TB IGRA + CXR. ART. |
| >350 | TB risk still elevated vs HIV-negative. Major OI risk substantially reduced. | Stop cotrimoxazole when CD4 >200 for 6+ months. Annual TB screen. | Cotrimoxazole can be stopped. Annual monitoring. Continue ART. |
CD4 Count vs Viral Load — Two Different Questions
CD4 count and viral load are both essential HIV monitoring tools but they answer different clinical questions. They must always be interpreted together — never in isolation.
Viral Load (HIV RNA)
How fast is the virus replicating?
CD4 Count
How much immune damage has occurred?
The Most Important Combined Reading
Undetectable viral load + Rising CD4: ART is working perfectly. The immune system is recovering. Continue ART and monitoring. Undetectable viral load + Stable/Low CD4: ART is working virologically but immune recovery is slow. Enhanced OI monitoring. Check for co-infections (TB, HBV). Detectable viral load + Falling CD4: treatment failure. Resistance testing and regimen change needed.
The CD4 Monitoring Schedule at SCID-AI
CD4 monitoring frequency is adjusted based on clinical status, time on ART, and viral load stability. The schedule below reflects current WHO and NACO guidelines as implemented at SCID-AI.
CD4 Recovery on ART — What to Expect
Most patients who start ART with a low CD4 count experience dramatic immune recovery. The pattern: 100–150 cells/mm³ increase in the first 3–6 months, followed by a slower sustained rise of 50–100 per year.
Patients who start with CD4 below 50 and achieve viral suppression may have slower recovery — some reach only 200–300 despite years of undetectable viral load. But even at CD4 200–300 with undetectable viral load, life expectancy on modern ART approaches normal. The CD4 number is one part of the clinical picture — viral suppression is the primary goal.
Starting ART with Very Low CD4
Patients who start ART with CD4 below 50 have Immune Reconstitution Inflammatory Syndrome (IRIS) risk — a paradoxical worsening of existing OIs as the immune system recovers. TB-IRIS is common in India. Dr. Savaj manages IRIS at SCID-AI and adjusts ART timing when active OIs are present.
The CD4 Rule
CD4 count tells you the degree of immune damage. Viral load tells you if ART is working. Both are needed together — every monitoring visit. The goal: undetectable viral load + rising CD4. Start ART regardless of CD4 count. Never stop ART. Adherence is everything — a missed dose is an invitation for resistance.
